Media stories about BioMarin Pharmaceutical (NASDAQ:BMRN) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.8083500107113 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of brokerages recently issued reports on BMRN. Wedbush reiterated a “neutral” rating and issued a $108.00 price target on shares of BioMarin Pharmaceutical in a research note on Monday, August 7th. SunTrust Banks, Inc. set a $115.00 target price on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Thursday, October 19th. J P Morgan Chase & Co set a $130.00 target price on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Sunday, October 29th. Leerink Swann restated an “outperform” rating and set a $142.00 target price (up previously from $136.00) on shares of BioMarin Pharmaceutical in a research note on Thursday, October 19th. Finally, Jefferies Group LLC restated a “buy” rating and set a $116.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, September 26th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the company’s stock. BioMarin Pharmaceutical has an average rating of “Hold” and an average price target of $111.55.
Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) opened at $81.41 on Wednesday. BioMarin Pharmaceutical has a fifty-two week low of $79.50 and a fifty-two week high of $100.51. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.91 and a quick ratio of 3.81.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. The company had revenue of $334.18 million during the quarter, compared to analyst estimates of $347.38 million. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The firm’s quarterly revenue was up 19.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.02 EPS. equities research analysts forecast that BioMarin Pharmaceutical will post -0.66 EPS for the current fiscal year.
In other BioMarin Pharmaceutical news, Director V Bryan Lawlis sold 3,750 shares of the stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $91.26, for a total transaction of $342,225.00. Following the completion of the sale, the director now directly owns 19,660 shares of the company’s stock, valued at approximately $1,794,171.60. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Robert Baffi sold 18,415 shares of the stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $92.43, for a total transaction of $1,702,098.45. Following the sale, the executive vice president now directly owns 129,083 shares of the company’s stock, valued at $11,931,141.69. The disclosure for this sale can be found here. Insiders sold a total of 40,686 shares of company stock valued at $3,736,318 over the last three months. 1.85% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/11/15/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-biomarin-pharmaceutical-bmrn-stock-price.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.